Physician profile
Jonathan A Baron
NPI 1982686333
$340,186.28
in general payments reported to CMS, 2019-2025
38 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $22K · 2021: $25K · 2022: $49K · 2023: $64K · 2024: $44K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Food and Beverage: $12K · Consulting Fee: $4,900 · Travel and Lodging: $1,882 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,520.00 |
| Food and Beverage | $11,650.43 |
| Consulting Fee | $4,900.00 |
| Travel and Lodging | $1,881.73 |
| Education | $118.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181,878.96 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $55,441.82 | 2019-2025 | Cosentyx |
| Amgen INC. | $47,855.27 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $37,218.33 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $4,046.65 | 2019-2025 | Tremfya, Simponi, Stelara |
| Celgene Corporation | $3,103.35 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,259.09 | 2019-2025 | Siliq, Targretin, Jublia |
| Genzyme Corporation | $1,645.25 | 2019-2025 | |
| Lilly USA, LLC | $1,288.96 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $833.13 | 2019-2025 | Ilumya |
| Almirall LLC | $815.49 | 2021-2023 | Seysara |
| Incyte Corporation | $794.87 | 2021-2025 | Opzelura |
| Pfizer INC. | $529.52 | 2019-2023 | |
| Galderma Laboratories, L.P. | $522.40 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $457.19 | 2020-2025 | Adbry, Anzupgo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.